| Autor: |
Hofste op Bruinink D; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . d.hofsteopbruinink@erasmusmc.nl., Oliva S; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy., Rihova L; Department of Hematology, University Hospital Brno, Brno, Czech Republic., Schmitz A; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Gilestro M; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy., Te Marvelde J; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands., Kralova R; Department of Hematology, University Hospital Brno, Brno, Czech Republic., Høholt H; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Broijl A; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Johnsen HE; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Hajek R; Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic., Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Omedè P; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy., Van der Velden VHJ; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . v.h.j.vandervelden@erasmusmc.nl. |
